Caris Life Sciences, Inc.
CAIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Caris Life Sciences, Inc. (CAI) is listed under Biotechnology. At a $4.66B market cap, Caris Life Sciences, Inc. ranks as a mid-cap company within healthcare. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Market Cap
$4.66B
Beta
—
P/E (TTM)
—
P/E (Fwd)
46.36
EPS (TTM)
$-2.76
EPS (Fwd)
$0.36
ROE
28.3%
ROA
9.3%
Cash
$823.5M
Total Debt
$431.0M
Free CF
$102.1M
52W Change
-45.4%
Annual Financials
Cash vs Debt
Caris Life Sciences, Inc. holds $823.5M in cash against $431.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $102.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 28.3% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 9.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $258.5M (2022) to $812.0M (2025), reflecting a 214% increase over the period.
Investors considering Caris Life Sciences, Inc. should weigh the typical risks associated with CAI's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Caris Life Sciences, Inc. and its sector.